论文部分内容阅读
目的探讨硝苯地平联合倍他乐克治疗老年顽固性高血压患者的有效性和安全性。方法选取2013年1月~2015年1月在我院就治的老年性顽固性高血压患者90例作为研究对象,随机分为观察组和对照组各45例。观察组采用硝苯地平联合倍他乐克治疗,对照组采用硝苯地平治疗。对两组患者治疗后的尿微量蛋白、尿肌酐、24小时动态血压、血清尿酸等进行检测,并统计用药过程中出现的不良反应。结果应用硝苯地平联合倍他乐克治疗后的观察组患者的指标的改善明显优于单纯使用硝苯地平的对照组,尿微量蛋白、尿肌酐、24小时动态血压、血清尿酸等相关指标比较,差异均有统计学意义(P<0.05)。观察组不良反应发生率为8.89%,对照组为11.11%,两组不良反应的比较,差异无统计学意义(P>0.05)。两组患者均未出现严重的不良反应。结论硝苯地平联用倍他乐克治疗老年顽固性高血压,疗效高于单一使用硝苯地平,并且有较好的安全性,值得临床推广和应用。
Objective To investigate the efficacy and safety of nifedipine and metoprolol in the treatment of senile patients with refractory hypertension. Methods Ninety elderly patients with refractory hypertension who were treated in our hospital from January 2013 to January 2015 were randomly divided into observation group (45 cases) and control group (45 cases). The observation group was treated with nifedipine and metoprolol, while the control group was treated with nifedipine. The urine microalbuminuria, urinary creatinine, 24-hour ambulatory blood pressure and serum uric acid were measured in two groups after treatment, and the adverse reactions in the course of treatment were counted. Results The improvement of the index of patients in the observation group treated with nifedipine and metoprolol was significantly better than that of the nifedipine-only control group. Urine microalbuminuria, urinary creatinine, 24-hour ambulatory blood pressure, serum uric acid and other related indicators , The differences were statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 8.89% and in the control group was 11.11%. There was no significant difference in adverse reactions between the two groups (P> 0.05). No serious adverse reactions occurred in both groups. Conclusion Nifedipine combined with Betaloc in the treatment of elderly patients with refractory hypertension, the effect is higher than the single use of nifedipine, and has good safety, worthy of clinical promotion and application.